xml version="1.0" encoding="utf-8" ?   8-K   

   false 0001136869        0001136869   2022-02-07 2022-02-07     0001136869  us-gaap:CommonStockMember    2022-02-07 2022-02-07     0001136869  zbh:M1.414NotesDue20223Member    2022-02-07 2022-02-07     0001136869  zbh:M2.425NotesDue20261Member    2022-02-07 2022-02-07     0001136869  zbh:M1.164NotesDue20272Member    2022-02-07 2022-02-07      

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): February 7, 2022 

ZIMMER BIOMET HOLDINGS, INC. 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

345 East Main Street 

Warsaw, Indiana 46580 

(Address of principal executive offices) (Zip Code) 

Registrant’s telephone number, including area code: (574) 267-6131 

Not applicable 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

   ☐  

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

   ☐  

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ 

 Item 7.01  

Regulation FD Disclosure  

On February 7, 2022, beginning at 11:00 a.m., Eastern Time, ZimVie Inc. (“ZimVie”), a wholly owned subsidiary of Zimmer Biomet Holdings, Inc. (the “Company”), is holding a virtual investor day event in connection with the Company’s previously announced plan to separate its dental and spine businesses into a standalone, publicly traded company through the spinoff of ZimVie.  

A copy of the investor presentation to be used in connection with the investor day event is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of this report. A live and archived webcast of the event can be accessed via the Company’s Investor Relations website at https://investor.zimmerbiomet.com.  

The press release issued on February 7, 2022 with respect to the investor day event, which also provides certain financial guidance with respect to ZimVie, is furnished as Exhibit 99.2 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of this report.  

The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.  

 Item 9.01  

Financial Statements and Exhibits.  

(d) Exhibits  

  [DATA_TABLE_REMOVED]  

SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  

Date: February 7, 2022  

 [DATA_TABLE_REMOVED]